cardiovascular

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. A closely watched cardiovascular drug from Novartis failed in a pivotal study, the company said Friday, a major blow to the firm and to efforts to target a common heart disease risk factor.  […]